July 30, 2025

ABL Diagnostics will become Vela Disgnostics's exclusive distributor in EMEA: a strategic alliance for a broader, integrated and automated molecular diagnostics offering

Singapore / Woippy, France – July 28, 2025
Vela Diagnostics, a global provider of integrated molecular diagnostics solutions, is pleased to announce a strategic channel partnership with ABL Diagnostics (Euronext: ABLD). Under this agreement, ABL will become the exclusive distributor of Vela’s CE-IVD automated PCR and NGS platforms across Europe, the Middle East, and Africa (EMEA), starting in January 2026, following a non-exclusive transition phase commencing in July 2025.

This alliance brings together Vela’s automation and validated assay portfolio with ABL’s specialized PCR/NGS kits and software platforms to deliver a complete, clinically relevant workflow for hospital and reference laboratories across the EMEA region.

Vela Diagnostics offers fully integrated sample-to-report molecular workflows across both PCR and NGS through its CE-IVD certified Sentosa^® platform. Designed to meet clinical requirements, these systems deliver lower turnaround time (TAT), reduced hands-on time (HOT), and high traceability—key attributes for laboratories operating in increasingly regulated and time-sensitive environments. In addition to automation, Vela has a proven ability to develop assays tailored to meet the specific clinical needs of its diverse customer base, ensuring relevance across infectious disease, oncology, and other fast-evolving diagnostic areas. The current portfolio includes pan-cancer NGS panels such as OncoKey^® SL 60 and SL 525 Plus, alongside a robust menu of infectious disease solutions including HIV genotyping via NGS, urinary tract infection (UTI) detection, and ISP and MRSA testing by PCR.

ABL Diagnostics brings over two decades of molecular diagnostics experience and has established itself as a scientific leader in infectious disease genotyping, PCR detection, and software analytics. Its DeepChek^® NGS software and UltraGene^® real-time PCR kits are widely adopted by clinical laboratories for the detection and resistance profiling of HIV, hepatitis viruses, tuberculosis, SARS-CoV-2, and other pathogens. ABL also provides the Nadis^® electronic medical record system, currently deployed in over 200 hospitals in France.

By combining ABL’s assay and software solutions with Vela’s automation and informatics systems, this partnership offers laboratories a truly harmonized solution—extending from sample preparation through to clinical reporting. The integration is designed to improve efficiency, streamline operations, and enhance diagnostic value while maintaining flexibility to adapt to emerging clinical needs and pathogen targets.

This collaboration reflects a broader shift in the molecular diagnostics industry toward integrated, end-to-end solutions. The Vela–ABL alliance provides an open yet standardized alternative for laboratories seeking to maintain both performance and adaptability.

“Partnering with ABL Diagnostics enables us to bring our advanced, CE-IVD automated workflows to EMEA through their well-established regional presence and software leadership,” said Sam Dajani, CEO and Chairman of Vela Diagnostics. “Together, we are delivering a more complete, scalable diagnostic solution for labs facing evolving testing challenges.”

“This alliance builds on ABL’s expertise in molecular software and broad assay menu, combined with Vela’s automation prowess and global support structure. It enables us to meet clients’ unmet needs with truly integrated solutions,” added Dr. Chalom Sayada, CEO of ABL Diagnostics.

The financial terms of the agreement were not disclosed.

About Vela Diagnostics

Vela Diagnostics is a global provider of integrated IVD test workflows, offering CE-IVD and FDA-cleared assays, automated instrumentation, and informatics for PCR and NGS-based infectious disease and oncology diagnostics. Its Sentosa^® platform is designed to optimize laboratory efficiency and clinical relevance across a wide range of applications. For more information, visit www.veladx.com.

About ABL Diagnostics

ABL Diagnostics (Euronext: ABLD) is a French-based molecular diagnostics company focused on PCR and NGS-based detection and genotyping, with proprietary software and assay solutions supporting the diagnosis and monitoring of infectious diseases. With distribution in over 40 countries and strong regional presence in Europe, ABL is at the forefront of innovation in digital microbiology and clinical genomics. For more information, visit www.abldiagnostics.com.

Media Contacts:
Sam Dajani, Chairman & CEO, Vela Diagnostics – sam.dajani@veladx.com
Dr. Chalom Sayada, CEO, ABL Diagnostics – info@abldiagnostics.com

Read more >